

## Author Index Volume 26 (2014)

The issue number is given in front of the page numbers

- Acheampong, F., B.P. Anto and G.A. Koffuor, Medication safety strategies in hospitals –  
A systematic review (3) 117–131
- Affi, S., N. Maharloui, P. Peymani, S. Namazi, A.G. Gharaei, P. Jahani and K.B. Lankarani,  
Adverse drug reactions reporting: Pharmacists' knowledge, attitude and practice in Shiraz,  
Iran (3) 139–145
- Anto, B.P., see Acheampong, F. (3) 117–131
- Bakhsh, H.T., S.J. Perona, W.A. Shields, S. Salek, A.B. Sanders and A.E. Patanwala, Medication  
errors in psychiatric patients boarded in the emergency department (4) 191–198
- Bang, V., A. Mallad, S. Kannan, S.B. Bavdekar, N.J. Gogtay and U.M. Thatte, Awareness  
about and views of parents on the off-label drug use in children (2) 61–70
- Bavdekar, S.B., see Bang, V. (2) 61–70
- Brookwell, L., C. Hogan, D. Healy and D. Mangin, Ninety-three cases of alcohol dependence  
following SSRI treatment (2) 99–107
- Card, A.J., M.C.E. Simsekler, M. Clark, J.R. Ward and P.J. Clarkson, Use of the Generating  
Options for Active Risk Control (GO-ARC) Technique can lead to more robust risk control  
options (4) 199–211
- Chopra, D., see Rehan, H.S. (1) 1–8
- Clark, M., see Card, A.J. (4) 199–211
- Clarkson, P.J., see Card, A.J. (4) 199–211
- Clarkson, P.J., see Horberry, T. (1) 23–37
- Curreen, M. and J. Lidmila, Zopiclone: Is there cause for concern in addiction services and  
general practice? (4) 183–189
- da Silva Dal Pizzol, T., see Maggi, C.B. (1) 9–22
- de Boer, A., see Warnier, M.J. (2) 89–98
- De Bruin, M.L., see Warnier, M.J. (2) 89–98
- Enoki, H., see Katahira, K. (4) 227–233
- Fontugne, E.A., The Affordable Care Act: Opportunities for collaboration between doctors and  
lawyers (2) 81–88
- Gharaei, A.G., see Affi, S. (3) 139–145
- Gogtay, N.J., see Bang, V. (2) 61–70
- Grech, V., Births and male:female birth ratio in Scandinavia and the United Kingdom  
after the Windscale fire of October 1957 (1) 45–53
- Griebeler, I.H., see Maggi, C.B. (1) 9–22

- Healy, D., G. Howe, D. Mangin and J.L. Noury, Sudden cardiac death & The Reverse Dodo Verdict (2) 71–79
- Healy, D., see Brookwell, L. (2) 99–107
- Healy, D., see Hogan, C. (2) 109–116
- Herxheimer, A., see Menkes, D.B. (3) 163–170
- Hoes, A.W., see Warnier, M.J. (2) 89–98
- Hogan, C., J.L. Noury, D. Healy and D. Mangin, One hundred and twenty cases of enduring sexual dysfunction following treatment (2) 109–116
- Hogan, C., see Brookwell, L. (2) 99–107
- Holani, S.N., see Rehan, H.S. (1) 1–8
- Holtkamp, F.A., see Warnier, M.J. (2) 89–98
- Horberry, T., Y.-C. Teng, J. Ward, V. Patil and P.J. Clarkson, Guidewire retention following central venous catheterisation: A human factors and safe design investigation (1) 23–37
- Howe, G., see Healy, D. (2) 71–79
- Izaham, A., see Mat, W.R.W. (2) 57–60
- Jaber, L., Preventive intervention for iron deficiency anaemia in a high risk population (3) 155–162
- Jahani, P., see Afifi, S. (3) 139–145
- Kannan, S., see Bang, V. (2) 61–70
- Katahira, K., T. Yoshikawa, H. Enoki, A. Teraoka and Y. Tsuchiya, Is the evidence of the Supreme Court Ruling of gefitinib litigation in Japan scientific? (4) 227–233
- Koffuor, G.A., see Acheampong, F. (3) 117–131
- Lankarani, K.B., see Afifi, S. (3) 139–145
- Lexchin, J. and B. Mintzes, A compromise too far: A review of Canadian cases of direct-to-consumer advertising regulation (4) 213–225
- Lidmila, J., see Curren, M. (4) 183–189
- Maggi, C.B., I.H. Griebeler and T. da Silva Dal Pizzol, Information on adverse events in randomised clinical trials assessing drug interventions published in four medical journals with high impact factors (1) 9–22
- Maharloui, N., see Afifi, S. (3) 139–145
- Mallad, A., see Bang, V. (2) 61–70
- Manap, N.A., see Mat, W.R.W. (2) 57–60
- Mangin, D., see Brookwell, L. (2) 99–107
- Mangin, D., see Healy, D. (2) 71–79
- Mangin, D., see Hogan, C. (2) 109–116
- Mat, W.R.W., N. Yahya, A. Izaham, R.A. Rahman, N.A. Manap and J.M. Zain, Near fatal error in management of postoperative epidural analgesia (2) 57–60
- Menkes, D.B. and A. Herxheimer, Interaction between antidepressants and alcohol: Signal amplification by multiple case reports (3) 163–170
- Mintzes, B., see Lexchin, J. (4) 213–225
- Mishra, R., see Rehan, H.S. (1) 1–8
- Mol, P.G.M., see Warnier, M.J. (2) 89–98
- Namazi, S., see Afifi, S. (3) 139–145
- Noury, J.L., see Healy, D. (2) 71–79
- Noury, J.L., see Hogan, C. (2) 109–116

- Patanwala, A.E., see Bakhsh, H.T. (4) 191–198
- Patil, V., see Horberry, T. (1) 23–37
- Perona, S.J., see Bakhsh, H.T. (4) 191–198
- Persaud, N., see Shoucri, R. (3) 147–153
- Peymani, P., see Afifi, S. (3) 139–145
- Pikkel, D., A. Sharabi-Nov and J. Pikkell, The importance of side marking in preventing surgical site errors (3) 133–138
- Pikkell, J., see Pikkell, D. (3) 133–138
- Rahman, R.A., see Mat, W.R.W. (2) 57–60
- Rehan, H.S., D. Chopra, S.N. Holani and R. Mishra, An observational study to compare the contents and quality of information furnished in CDSCO ADR reporting form, yellow card, medwatch and blue form by the healthcare professionals (1) 1–8
- Rutten, F.H., see Warnier, M.J. (2) 89–98
- Salek, S., see Bakhsh, H.T. (4) 191–198
- Sanders, A.B., see Bakhsh, H.T. (4) 191–198
- Sharabi-Nov, A., see Pikkell, D. (3) 133–138
- Shields, W.A., see Bakhsh, H.T. (4) 191–198
- Shoucri, R. and N. Persaud, Investigating pharmaceutical marketing in Canada using American prosecutions (3) 147–153
- Simsekler, M.C.E., see Card, A.J. (4) 199–211
- Teng, Y.-C., see Horberry, T. (1) 23–37
- Teraoka, A., see Katahira, K. (4) 227–233
- Thatte, U.M., see Bang, V. (2) 61–70
- Tsuchiya, Y., see Katahira, K. (4) 227–233
- Ward, J., see Horberry, T. (1) 23–37
- Ward, J.R., see Card, A.J. (4) 199–211
- Warnier, M.J., F.A. Holtkamp, F.H. Rutten, A.W. Hoes, A. de Boer, P.G.M. Mol and M.L. De Bruin, Quality of drug label information on QT interval prolongation (2) 89–98
- Yahya, N., see Mat, W.R.W. (2) 57–60
- Yoshikawa, T., see Katahira, K. (4) 227–233
- Yudina, E.V. and L.E. Ziganshina, Palivizumab and respiratory syncytial virus disease: Selling sickness for future? (1) 39–43
- Zain, J.M., see Mat, W.R.W. (2) 57–60
- Ziganshina, L.E., see Yudina, E.V. (1) 39–43